Similar articles for PMID: 33526466

Year	Number of Results
2005	1
2009	1
2010	1
2011	7
2012	3
2013	6
2014	7
2015	8
2016	9
2017	13
2018	9
2019	18
2020	11
2021	10
2022	2
2023	2
2024	0

1

Precision treatment for metastatic non-small cell lung cancer: A conceptual overview.

Lee T, Clarke JM, Jain D, Ramalingam S, Vashistha V. Lee T, et al. Cleve Clin J Med. 2021 Feb 1;88(2):117-127. doi: 10.3949/ccjm.88a.19148. Cleve Clin J Med. 2021. PMID: 33526466 Free article. Review.

2

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.

Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981

3

Targeted Therapies in Non-small-Cell Lung Cancer.

Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R. Hill A, et al. Cancer Treat Res. 2019;178:3-43. doi: 10.1007/978-3-030-16391-4_1. Cancer Treat Res. 2019. PMID: 31209840

4

Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.

Yin JY, Li X, Zhou HH, Liu ZQ. Yin JY, et al. Pharmacogenomics. 2016 Aug;17(12):1365-78. doi: 10.2217/pgs-2016-0074. Epub 2016 Jul 27. Pharmacogenomics. 2016. PMID: 27462924 Review.

5

Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.

Remon J, Tabbò F, Jimenez B, Collazo A, de Castro J, Novello S. Remon J, et al. Clin Transl Oncol. 2020 Sep;22(9):1425-1429. doi: 10.1007/s12094-020-02290-1. Epub 2020 Jan 18. Clin Transl Oncol. 2020. PMID: 31955355 Review.

6

A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.

Chen L, Smith DA, Somarouthu B, Gupta A, Gilani KA, Ramaiya NH. Chen L, et al. AJR Am J Roentgenol. 2019 Nov;213(5):1047-1058. doi: 10.2214/AJR.19.21135. Epub 2019 Jul 30. AJR Am J Roentgenol. 2019. PMID: 31361530 Review.

7

Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer.

Rivera-Concepcion J, Uprety D, Adjei AA. Rivera-Concepcion J, et al. Cancer Res Treat. 2022 Apr;54(2):315-329. doi: 10.4143/crt.2022.078. Epub 2022 Feb 18. Cancer Res Treat. 2022. PMID: 35209703 Free PMC article. Review.

8

Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.

Reckamp KL. Reckamp KL. J Natl Compr Canc Netw. 2018 May;16(5S):601-604. doi: 10.6004/jnccn.2018.0046. J Natl Compr Canc Netw. 2018. PMID: 29784736

9

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.

Lammers PE, Lovly CM, Horn L. Lammers PE, et al. J Natl Compr Canc Netw. 2014 Jan;12(1):6-11; quiz 11. doi: 10.6004/jnccn.2014.0002. J Natl Compr Canc Netw. 2014. PMID: 24453288 Free PMC article.

10

NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?

Falk AT, Heeke S, Hofman V, Lespinet V, Ribeyre C, Bordone O, Poudenx M, Otto J, Garnier G, Castelnau O, Guigay J, Leroy S, Marquette CH, Hofman P, Ilié M. Falk AT, et al. Expert Rev Anticancer Ther. 2017 Aug;17(8):681-685. doi: 10.1080/14737140.2017.1331736. Epub 2017 May 22. Expert Rev Anticancer Ther. 2017. PMID: 28511612

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

96 results

Results by year